Chyou-Shen Lee

Chyou-Shen Lee

Auto-generated profile, based on publicly available information

Chyou-Shen Lee

Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2010 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Closed access
TYTzu Lin Yeh
Tzu Lin Yeh
FHFu-Yuan Huang
Fu-Yuan Huang
SSShyh-Dar Shyur
Shyh-Dar Shyur
TCTien-Ling Chen
Tien-Ling Chen
CLChyou-Shen Lee
Chyou-Shen Lee
DHDaniel Tsung-Ning Huang
Daniel Tsung-Ning Huang

30 June 2020 in Archives of Rheumatology
Verified
Journal Article
Open access
PDF file
TLToong-Hua Liang
Toong-Hua Liang
CLChyou-Shen Lee
Chyou-Shen Lee
SLShinn-Shing Lee
Shinn-Shing Lee
CWChien-Sheng Wu
Chien-Sheng Wu
KCKun-Hung Chen
Kun-Hung Chen
HLHsiao-Yi Lin
Hsiao-Yi Lin
Objectives: This study aims to evaluate the efficacy and safety profile of opinercept for rheumatoid arthritis (RA) patients undergoing disease- modifying anti-rheumatic drugs (DMARDs) therapy. Patients and methods: A total of 98 patients with active RA (17 males, 81 females; mean age 58.6±12.2 years; range, 24.3 to 85.3 years) were randomized into opinercept plus DMARDs (OD group) or placebo plus DMARDs (PD group), in a 24-week treatment period. Primary outcome was American College of Rheumatology score (ACR20) at week 24. Other exploratory endpoints included ACR50, ACR70 and disease activity score-28 (DAS28) at week 12 and 24, tender/swollen joint counts, pain, Health Assessment Questionnaire-Disability Index, erythrocyte sedimentation rate, and C-reactive protein level. Incidence of adverse events (AEs), vital signs and physical findings, and laboratory test results were also evaluated. Results: Patients in OD group showed significantly higher achievement percentage of ACR20 at week 24 than the PD group (76.6% vs. 30.3%, p